MET Exon 14 Skipping Mutations in Non–Small Cell Lung Cancer

home / insights / met-exon-14-skipping-mutations-non-small-cell-lung-cancer

MET Exon 14 Skipping Mutations in NSCLC

EP. 1: MET Exon 14 Skipping Mutations in NSCLC

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
March 29th 2021
Advances in Targeting MET Exon 14 Skipping Mutations in NSCLC

EP. 2: Advances in Targeting MET Exon 14 Skipping Mutations in NSCLC

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
March 29th 2021
Testing to Identify MET Exon 14 Mutations in NSCLC 

EP. 3: Testing to Identify MET Exon 14 Mutations in NSCLC 

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 5th 2021
Capmatinib for MET Exon 14-Mutated NSCLC

EP. 4: Capmatinib for MET Exon 14-Mutated NSCLC

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 5th 2021
Tepotinib for MET Exon 14 Skipping Mutations in NSCLC

EP. 5: Tepotinib for MET Exon 14 Skipping Mutations in NSCLC

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 12th 2021
CNS Response to MET Inhibition in NSCLC

EP. 6: CNS Response to MET Inhibition in NSCLC

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 12th 2021
MET Inhibitors in NSCLC: Treatment Selection

EP. 7: MET Inhibitors in NSCLC: Treatment Selection

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 19th 2021
MET Inhibitors in NSCLC: Toxicity Management

EP. 8: MET Inhibitors in NSCLC: Toxicity Management

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 19th 2021
MET Inhibitors in NSCLC: Mechanisms of Resistance

EP. 9: MET Inhibitors in NSCLC: Mechanisms of Resistance

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 26th 2021
Current and Future Use of MET Inhibitors in NSCLC

EP. 10: Current and Future Use of MET Inhibitors in NSCLC

Lyudmila A. Bazhenova, MD, University of California San Diego;Joshua M. Bauml, MD, Perelman School of Medicine;Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center
April 26th 2021